First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients

Table 3

Factors associated with overall survival time of Chinese subjects with NSCLC.

Factors and gene expression	Number of patients	Median survival time (month)	Univariate analysis		Multivariate analysis
			Logrank	𝑃	HR	95% CI	𝑃
Age
>65	11	12.0	0.065	0.799	—	—	—
<65	23	12.5			—	—	—
Smoker
Yes	13	12.0	0.008	0.927	—	—	—
No	21	13.0			—	—	—
Stage
IIIB	9	12.0	0.169	0.681	—	—	—
IV	25	13.0			—	—	—
Histology
Squamous cell carcinoma	10	11.0	2.801	0.094	—	—	—
Adenocarcinoma	24	13.0			—	—	—
Response
Partial	10	12.5	16.154	0.0001	0.614	0.267–2.468	0.017
Stable/progressive	24	12.0			1
RRM1
Low	17	15.5	3.980	0.046	2.574	0.886–7.479	0.082
High	17	12.0			1
ERCC1
Low	17	15.5	1.124	0.289	—	—	—
High	17	13.0			—	—	—
BRCA1
Low	17	13.0	0.702	0.402	—	—	—
High	17	15.5			—	—	—